MedTrace Logo

Yttrium-90 (Y90) Glass Microspheres PET/CT in Imaging Patients With Liver Tumors

NCT03109262 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 42

Last updated 2022-01-10

Study results available
· View outcomes & findings →

Summary

This clinical trial studies how well yttrium-90 (Y90) glass microspheres positron emission tomography (PET)/computed tomography (CT) works in imaging patients with liver tumors . Images produced by PET/CT may provide better information about the distribution of particles, such as Y90 glass microspheres, delivered for selective internal radiation therapy (SIRT) as compared to regular medical care images useing technetium Tc-99m albumin-aggregated single photon emission computed tomography (SPECT)/CT images.

Conditions

  • Primary Malignant Liver Neoplasm

Interventions

PROCEDURE

Computed Tomography (CT)

As part of PET/CT and SPECT/CT scans.

PROCEDURE

Positron Emission Tomography (PET)

As part of PET/CT scan

DEVICE

90-Yttrium (Y-90) Glass Microspheres

Radiolabel for PET/CT scan

DIAGNOSTIC_TEST

Technetium 99mTc albumin aggregated (99mTc-MAA)

Radiolabel for 99mTc-MAA SPECT/CT Scan

PROCEDURE

Single-photon emission computerized tomography (SPECT) scan

As part of SPECT/CT scan

Sponsors & Collaborators

Principal Investigators

  • Andrei Iagaru · Stanford University

Study Design

Allocation
NA
Purpose
DIAGNOSTIC
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-02-15
Primary Completion
2019-05-30
Completion
2021-02-28
FDA Device
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03109262 on ClinicalTrials.gov